Systematic review of immunomodulatory therapies for hidradenitis suppurativa
Open Access
- 1 May 2019
- journal article
- review article
- Published by Taylor & Francis in Biologics: Targets and Therapy
- Vol. ume 13, 53-78
Abstract
Background: Greater understanding of the roles of tumor necrosis factor-α, IL-1β, IL-10, and the IL-23/T-helper (Th) 17 and IL-12/Th1 pathways in immune dysregulation in moderate/severe hidradenitis suppurativa (HS) has helped in developing new regimens. We aim to review the use of different immunomodulatory therapies used to manage HS. Methods: A comprehensive literature search was conducted on the PubMed and Clinicaltrials.gov databases from 1 January 1947 to 31 December 2018. Only clinical trials, case reports, case series and retrospective analyses published in the English language were included. Results: Our search yielded 107 articles and 35 clinical trials, of which 15 are still ongoing. The tumor necrosis factor-α inhibitors adalimumab and infliximab were the most comprehensively studied agents. Published data from clinical trials support the efficacy of adalimumab, infliximab, anakinra, ustekinumab, bermekimab and apremilast but not etanercept and MEDI8968. Clinical trials for CJM112 have been completed, with results awaiting publication. Trials are underway for secukinumab, IFX-1, INCB054707 and bimekizumab. Biologics used in smaller cohorts include canakinumab, golimumab and rituximab. Most agents are well tolerated and demonstrate a good safety profile, with the most commonly reported adverse event being infections. Discussion and conclusions: To date, adalimumab is the only biologic which has been approved by the United States Food and Drug Administration for HS. However, other agents also show promise, with further trials underway to evaluate their efficacy, tolerability and safety profiles. Different clinical measurement scores and endpoints used to make direct comparison difficult. Longitudinal surveillance and pooled registry data are paramount to evaluate the long-term safety profile and efficacy of therapy.Keywords
This publication has 121 references indexed in Scilit:
- Paradoxical effect of infliximab in a patient with hidradenitis suppurativaDermatologic Therapy, 2012
- Gemella morbillorum Bacteremia after Anti-Tumor Necrosis Factor Alpha as Acne Inversa TherapyJournal of Clinical Microbiology, 2012
- A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the kneeArthritis Research & Therapy, 2011
- Effective long‐term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapyInternational Journal of Dermatology, 2010
- A phase 2 randomized, double-blind study of AMG 108, a fully human monoclonal antibody to IL-1R, in patients with rheumatoid arthritisArthritis Research & Therapy, 2010
- Hidradenitis suppurativa responding to treatment with infliximabAustralasian Journal of Dermatology, 2010
- A prospective open‐label clinical trial of adalimumab for the treatment of hidradenitis suppurativaInternational Journal of Dermatology, 2010
- A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativaJournal of the American Academy of Dermatology, 2009
- Successful Treatment of Recalcitrant Hidradenitis Suppurativa with AdalimumabCase Reports in Dermatology, 2009
- Infliximab for the treatment of hidradenitis suppurativaJournal of the American Academy of Dermatology, 2003